In Breast cancer, approved immunotherapy is restricted to metastatic PDL1+ TNBC tumors, with only 13% of patients receiving anti-PDL1 treatment (Atezolizumab) experiencing a significant response rates, longer overall survival, and higher immune cell infiltration (46–48). This evidence concerns the gene CD274 and breast cancer.